secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-206360
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics reports Q1 2026: MYQORZO net product rev $4.8M, net loss $206M; ACACIA-HCM meets endpoints
--------------------------------------------------------------------------------

- MYQORZO net product revenue $4.8M for ~9 weeks; total revenue $19.4M (incl $11.9M milestone from Bayer).
- Net loss $206.0M ($1.67/sh) vs $161.4M loss in Q1 2025; cash $1.1B (down $144M from Dec 2025).
- ACACIA-HCM met dual primary endpoints (KCCQ and peak VO2) in non-obstructive HCM; full results at upcoming medical congress.
- Over 275 HCPs prescribed MYQORZO to ~680 patients in Q1; European Commission approved for oHCM.
- FY 2026 GAAP combined R&D and SG&A guidance maintained at $830M-$870M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/0001193125-26-206360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-206360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer